Keros Therapeutics, Inc. Common Stock — Quarterly Financial Statements (NASDAQ:KROS) | MetaTrader

Open full chart

Financials

Overview Statement Statistics

Quarterly Annual

Market Capitalization 229.5121 M
Employee 78
Founded 2015
CEO N/A
Website www.kerostx.com
Headquarter Massachusetts, United States
FIGI BBG00H1HP9G9
Industry Biotechnology

Total revenue

Net income

Basic earnings per share (Basic EPS)

Total debt

Free cash flow

Cash & equivalents

229.51 M Market capitalization

Price to earnings ratio

8.85

Price to sales ratio

3.16

News

Insmed (INSM) Soars 5.5%: Is Further Upside Left in the Stock?

KROS: Is the Discount Book Value a Value Trap?

KROS Stock: What to Know About Rinvatercept in DMD

KROS Pipeline Catalysts: DMD Phase II and ALS Plans for 2026

Can Keros Therapeutics Rinvatercept Stand Out in the DMD Market?

Can Reblozyl Stabilize BMY's Top Line Amid Legacy Drugs Decline?

Keros Therapeutics, Inc. (KROS) Reports Q4 Loss, Misses Revenue Estimates

Keros earnings missed by $0.16, revenue fell short of estimates

Should Investors Buy, Sell or Hold KROS Stock Ahead of Q4 Earnings?

Will Reblozyl Shine in Bristol Myers' Fourth-Quarter Results?

SRPT Stock Up 8% on Positive Long-Term Data From Elevidys Study in DMD

Keros Therapeutics vs. Dyne: Which DMD Biotech Has More Upside?